Heparin and its derivatives in the treatment of arterial thrombosis: a review

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F10%3A00046985" target="_blank" >RIV/00216224:14110/10:00046985 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/62157124:16170/10:00003010

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Heparin and its derivatives in the treatment of arterial thrombosis: a review

Popis výsledku v původním jazyce

Arterial occlusion due to thrombosis caused by ruptured atherosclerotic plaques has been recognized as a major cause of morbidity and mortality in western populations. Along with chronic heart failure it significantly decreases patient life expectancy. The major goal of treatment remains fast recanalization and acute reocclusion prevention. Direct (antithrombin-independent) thrombin inhibitors can be divided into two main categories: monovalent and bivalent, while antithrombin stimulators represent standard (unfractionated) heparin (UFH) and its depolymerizing products - low molecular weight heparins (LMWH's). Recently a shift to prophylaxis of thromboembolic disease has been advocated. Unlike standard heparin, low-molecular weight heparins do not affect the patient's general coagulation profile. Obviously, the difference in molecular weight results in different pharmacokinetic and pharmacodynamic properties of the agents.

Název v anglickém jazyce

Heparin and its derivatives in the treatment of arterial thrombosis: a review

Popis výsledku anglicky

Arterial occlusion due to thrombosis caused by ruptured atherosclerotic plaques has been recognized as a major cause of morbidity and mortality in western populations. Along with chronic heart failure it significantly decreases patient life expectancy. The major goal of treatment remains fast recanalization and acute reocclusion prevention. Direct (antithrombin-independent) thrombin inhibitors can be divided into two main categories: monovalent and bivalent, while antithrombin stimulators represent standard (unfractionated) heparin (UFH) and its depolymerizing products - low molecular weight heparins (LMWH's). Recently a shift to prophylaxis of thromboembolic disease has been advocated. Unlike standard heparin, low-molecular weight heparins do not affect the patient's general coagulation profile. Obviously, the difference in molecular weight results in different pharmacokinetic and pharmacodynamic properties of the agents.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FJ - Chirurgie včetně transplantologie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2010

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Veterinární medicína

ISSN

0375-8427

e-ISSN

—

Svazek periodika

55

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

24

Strana od-do

—

Kód UT WoS článku

000285646900001

EID výsledku v databázi Scopus

—